title: A randomized, open-label study of a nucleoside analogue reverse transcriptase inhibitor-sparing regimen in antiretroviral-naive HIV-infected patients.
authors.forename: Marianne
authors.initials: M
authors.lastname: Harris
authors.forename: Hélène
authors.initials: H
authors.lastname: Côté
authors.forename: Claudia
authors.initials: C
authors.lastname: Ochoa
authors.forename: Clotilde
authors.initials: C
authors.lastname: Allavena
authors.forename: Eugenia
authors.initials: E
authors.lastname: Negredo
authors.forename: Anona
authors.initials: A
authors.lastname: Thorne
authors.forename: Pedro
authors.initials: P
authors.lastname: Cahn
authors.forename: Carlos
authors.initials: C
authors.lastname: Zala
authors.forename: Francois
authors.initials: F
authors.lastname: Raffi
authors.forename: Bonaventura
authors.initials: B
authors.lastname: Clotet
authors.forename: Joel
authors.initials: J
authors.lastname: Singer
authors.forename: Julio
authors.initials: J
authors.lastname: Montaner
mesh_terms: D000328:Adult; D018791:CD4 Lymphocyte Count; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage / Q000627:therapeutic use; D061466:Lopinavir; D008297:Male; D019829:Nevirapine / Q000008:administration & dosage / Q000627:therapeutic use; D011744:Pyrimidinones / Q000008:administration & dosage / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D019438:Ritonavir / Q000008:administration & dosage / Q000627:therapeutic use; D019562:Viral Load; D015215:Zidovudine / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D018894:Reverse Transcriptase Inhibitors; D061466:Lopinavir; D019259:Lamivudine; D015215:Zidovudine; D019829:Nevirapine; D019438:Ritonavir